Koers Adynxx, Inc. Other OTC
Aandelen
ADYX
US00784D1037
Biotechnologie & Medisch Onderzoek
Omzet 2017 | - | Omzet 2018 | - | Marktkapitalisatie | 5 4,61 |
---|---|---|---|---|---|
Nettowinst (verlies) 2017 | -11 mln. -10,14 mln. | Nettowinst (verlies) 2018 | -5 mln. -4,61 mln. | EV/omzet 2017 * | - |
Nettoliquiditeiten 2017 * | - 0 | Nettoliquiditeiten 2018 * | - 0 | EV/omzet 2018 * | - |
K/w-verhouding 2017 * |
-
| K/w-verhouding 2018 * |
-
| Werknemers | - |
Dividendrendement 2017 * |
-
| Dividendrendement 2018 * |
-
| Vrij verhandelbaar | 100% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Julien Mamet
FOU | Founder | - | 01-10-07 |
Rick Orr
CEO | Chief Executive Officer | - | 01-12-10 |
Dina Gonzalez
DFI | Director of Finance/CFO | - | 01-01-10 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Eckard Weber
BRD | Director/Board Member | 73 | - |
Stanley Abel
BRD | Director/Board Member | - | 01-01-08 |
Dennis Podlesak
CHM | Chairman | 66 | - |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+63,77% | 62,86 mld. | |
-1,03% | 41,38 mld. | |
+45,55% | 40,38 mld. | |
-8,93% | 27,64 mld. | |
+12,92% | 26,46 mld. | |
-22,62% | 18,9 mld. | |
+3,98% | 12,67 mld. | |
+25,07% | 12,27 mld. | |
+28,62% | 12,07 mld. |